康希诺生物公司已开展新冠疫苗适用年龄拓展的相关工作

2022-10-30

消息面上，上海市于10月26日起启动吸入用重组新冠病毒疫苗（5型腺病毒载体）加强免疫。康希诺生物在互动平台表示，公司的腺病毒载体新冠疫苗获批用于18岁及以上人群，公司已完成向18岁以下年龄组的扩展进行的相应临床试验并积累相关数据，会与监管机构保持沟通寻求扩展年龄组的可能。

瑞银表示，未来吸入式新冠疫苗或将成为主流，因其直接在上呼吸道产生抗体，有望逐渐取代注射式疫苗，且副作用较少及管理过程较为简单。浙商证券则表示，康希诺生物吸入用重组新型冠状病毒疫苗作为加强针被纳入紧急使用，看好公司产品获批下的增长潜力。

$康希诺(688185)$ $康希诺生物(06185)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

低买高卖谁不会
2022-10-30
低买高卖谁不会
$康希诺(688185)$股价是不是短线有回调的压力?
福斯特09
2022-10-30
福斯特09
在上呼吸道产生抗体是疫苗还是很有前景的
沙漠追光大海逐风
2022-10-30
沙漠追光大海逐风
看了一眼这公司股价走势，看着是真的不错

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":665127642,"tweetId":"665127642","gmtCreate":1667102300887,"gmtModify":1667102490003,"author":{"id":3579227264236560,"idStr":"3579227264236560","authorId":3579227264236560,"authorIdStr":"3579227264236560","name":"四处观察","avatar":"https://static.tigerbbs.com/768271b1648a863180be0b78ef784553","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"康希诺生物公司已开展新冠疫苗适用年龄拓展的相关工作","html":"<html><head></head><body>消息面上，上海市于10月26日起启动吸入用重组新冠病毒疫苗（5型腺病毒载体）加强免疫。康希诺生物在互动平台表示，公司的腺病毒载体新冠疫苗获批用于18岁及以上人群，公司已完成向18岁以下年龄组的扩展进行的相应临床试验并积累相关数据，会与监管机构保持沟通寻求扩展年龄组的可能。 瑞银表示，未来吸入式新冠疫苗或将成为主流，因其直接在上呼吸道产生抗体，有望逐渐取代注射式疫苗，且副作用较少及管理过程较为简单。浙商证券则表示，康希诺生物吸入用重组新型冠状病毒疫苗作为加强针被纳入紧急使用，看好公司产品获批下的增长潜力。 <a target=\"_blank\" href=\"https://laohu8.com/S/688185\">$康希诺(688185)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/06185\">$康希诺生物(06185)$</a>&nbsp;</body></html>","htmlText":"<html><head></head><body>消息面上，上海市于10月26日起启动吸入用重组新冠病毒疫苗（5型腺病毒载体）加强免疫。康希诺生物在互动平台表示，公司的腺病毒载体新冠疫苗获批用于18岁及以上人群，公司已完成向18岁以下年龄组的扩展进行的相应临床试验并积累相关数据，会与监管机构保持沟通寻求扩展年龄组的可能。 瑞银表示，未来吸入式新冠疫苗或将成为主流，因其直接在上呼吸道产生抗体，有望逐渐取代注射式疫苗，且副作用较少及管理过程较为简单。浙商证券则表示，康希诺生物吸入用重组新型冠状病毒疫苗作为加强针被纳入紧急使用，看好公司产品获批下的增长潜力。 <a target=\"_blank\" href=\"https://laohu8.com/S/688185\">$康希诺(688185)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/06185\">$康希诺生物(06185)$</a>&nbsp;</body></html>","text":"消息面上，上海市于10月26日起启动吸入用重组新冠病毒疫苗（5型腺病毒载体）加强免疫。康希诺生物在互动平台表示，公司的腺病毒载体新冠疫苗获批用于18岁及以上人群，公司已完成向18岁以下年龄组的扩展进行的相应临床试验并积累相关数据，会与监管机构保持沟通寻求扩展年龄组的可能。 瑞银表示，未来吸入式新冠疫苗或将成为主流，因其直接在上呼吸道产生抗体，有望逐渐取代注射式疫苗，且副作用较少及管理过程较为简单。浙商证券则表示，康希诺生物吸入用重组新型冠状病毒疫苗作为加强针被纳入紧急使用，看好公司产品获批下的增长潜力。 $康希诺(688185)$ $康希诺生物(06185)$","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/665127642","repostId":0,"isVote":1,"tweetType":1,"viewCount":2280,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["688185","06185"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":516,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":7717972,"commentId":"7717972","gmtCreate":1667103436944,"gmtModify":1667103441401,"authorId":9000000000000311,"author":{"id":9000000000000311,"idStr":"9000000000000311","authorId":9000000000000311,"name":"低买高卖谁不会","avatar":"https://static.tigerbbs.com/07bc9bca07cec671db72f7d6b853211d","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":665127642,"objectIdStr":"665127642","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"$康希诺(688185)$股价是不是短线有回调的压力?","text":"$康希诺(688185)$股价是不是短线有回调的压力?","html":"$康希诺(688185)$股价是不是短线有回调的压力?","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":7717974,"commentId":"7717974","gmtCreate":1667103526596,"gmtModify":1667103530458,"authorId":9000000000000307,"author":{"id":9000000000000307,"idStr":"9000000000000307","authorId":9000000000000307,"name":"福斯特09","avatar":"https://static.tigerbbs.com/e0718fadae159e83dfa236747cbf442c","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":665127642,"objectIdStr":"665127642","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"在上呼吸道产生抗体是疫苗还是很有前景的","text":"在上呼吸道产生抗体是疫苗还是很有前景的","html":"在上呼吸道产生抗体是疫苗还是很有前景的","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":7717971,"commentId":"7717971","gmtCreate":1667103401544,"gmtModify":1667103405503,"authorId":9000000000000220,"author":{"id":9000000000000220,"idStr":"9000000000000220","authorId":9000000000000220,"name":"沙漠追光大海逐风","avatar":"https://static.tigerbbs.com/e30b7f24ce0a6599dcdfa3567f958dea","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":665127642,"objectIdStr":"665127642","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"看了一眼这公司股价走势，看着是真的不错","text":"看了一眼这公司股价走势，看着是真的不错","html":"看了一眼这公司股价走势，看着是真的不错","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/665127642"}